A phase II study of gemcitabine (GEMZAR) and irinotecan (CPT-11) in previously untreated patients with measurable disease with unknown primary carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2012 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.